



Yamhill County
Health and Human Services
Public Health

ALERT

**COPY AND DISTRIBUTE TO
Health Care Providers**

To: Health Care Providers in Yamhill County

From: Yamhill County Public Health
Fax number: (503) 472-9731

Date: **8/9/21**

Regarding: ***Oregon Immunization Program:
Off-Label COVID-19 Vaccine Use,
Monoclonal Antibody Therapies***

Phone number for follow-up: **(503) 434-7483**

Please see the below message from the Oregon Immunization Program.

IMPORTANT REMINDER: The COVID-19 vaccine provider agreement does NOT allow for off-label use of the vaccine, including additional doses such as a second dose after a Johnson & Johnson or a third dose after a Pfizer or Moderna series.

Oregon Health Authority continues to endorse CDC and ACIP recommendations for COVID-19 vaccine dosing. Under current conditions, CDC and ACIP do not recommend administering booster doses of the COVID-19 vaccines. Administering a booster to an individual is outside the scope of the FDA emergency use authorization (EUA). **Providers writing prescriptions for additional doses of vaccine should note that this practice is outside of the EUA and not recommended.** Boosters recommended by a physician beyond the EUA scope should be discussed directly with the manufacturer and FDA. Vaccines given according to the currently recommended schedule continue to be highly effective in reducing the risk of serious illness from COVID-19. Observational data confirm that currently available vaccines are effective against new variants, including the Delta variant.

For providers with concerns about fully vaccinated people who may still be at ongoing risk for COVID-19, monoclonal antibody therapies have now been expanded to include post-exposure prophylaxis including for those individuals who are fully vaccinated but thought to not be able to mount a sufficient immune response such as immunocompromised individuals and those on immunosuppressive medications and therefore at higher risk of COVID-19. **Monoclonal antibody therapies are now available in subcutaneous in addition to intravenous formulation.** Here is a link to the CDC's [COVID-19 Monoclonal Antibody Therapeutics Communications Toolkit](#) for health care providers, health system administrators, treatment sites, and others.